BR112022011123A2 - Composto, processo para a preparação de um composto, usos de um composto, métodos para o tratamento de câncer e invenção - Google Patents

Composto, processo para a preparação de um composto, usos de um composto, métodos para o tratamento de câncer e invenção

Info

Publication number
BR112022011123A2
BR112022011123A2 BR112022011123A BR112022011123A BR112022011123A2 BR 112022011123 A2 BR112022011123 A2 BR 112022011123A2 BR 112022011123 A BR112022011123 A BR 112022011123A BR 112022011123 A BR112022011123 A BR 112022011123A BR 112022011123 A2 BR112022011123 A2 BR 112022011123A2
Authority
BR
Brazil
Prior art keywords
compound
cancer
preparing
treatment
methods
Prior art date
Application number
BR112022011123A
Other languages
English (en)
Inventor
Dolente Cosimo
Stephen HEWINGS David
Hunziker Daniel
Krummenacher Daniela
Francesco Tommaso Pettazzoni Piergiorgio
Wichmann Juergen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112022011123A2 publication Critical patent/BR112022011123A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

COMPOSTO, PROCESSO PARA A PREPARAÇÃO DE UM COMPOSTO, USOS DE UM COMPOSTO, MÉTODOS PARA O TRATAMENTO DE CÂNCER E INVENÇÃOA. invenção fornece novos compostos que têm a fórmula geral (I) (I), ou um sal farmaceuticamente aceitável do mesmo. O composto de fórmula (I) pode ser usado como um medicamento.
BR112022011123A 2019-12-10 2020-12-08 Composto, processo para a preparação de um composto, usos de um composto, métodos para o tratamento de câncer e invenção BR112022011123A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19214941 2019-12-10
PCT/EP2020/084976 WO2021116055A1 (en) 2019-12-10 2020-12-08 New methylquinazolinone derivatives

Publications (1)

Publication Number Publication Date
BR112022011123A2 true BR112022011123A2 (pt) 2022-08-23

Family

ID=68848113

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011123A BR112022011123A2 (pt) 2019-12-10 2020-12-08 Composto, processo para a preparação de um composto, usos de um composto, métodos para o tratamento de câncer e invenção

Country Status (18)

Country Link
US (1) US20220298119A1 (pt)
EP (1) EP4073065A1 (pt)
JP (2) JP7108146B2 (pt)
KR (1) KR20220110554A (pt)
CN (1) CN114787156A (pt)
AR (1) AR122351A1 (pt)
AU (1) AU2020403443B2 (pt)
BR (1) BR112022011123A2 (pt)
CA (1) CA3162883A1 (pt)
CL (1) CL2022001529A1 (pt)
CO (1) CO2022008968A2 (pt)
CR (1) CR20220251A (pt)
IL (1) IL292161A (pt)
MX (1) MX2022006783A (pt)
PE (1) PE20221778A1 (pt)
TW (1) TW202136245A (pt)
WO (1) WO2021116055A1 (pt)
ZA (1) ZA202204675B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022289684A1 (en) * 2021-06-09 2023-10-05 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
WO2022258612A1 (en) * 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
IL308632A (en) * 2021-06-09 2024-01-01 Hoffmann La Roche NEW SOLID FORMS OF (3R)-N-[2-CYANO-4-FLUORO-3-(3-MTHYL-4-OXO-QUINZOLIN-6-YL)OXY-PHENYL]-3-FLUORO-PYRROLIDINE-1-SULFONAMIDE
JPWO2023008462A1 (pt) 2021-07-27 2023-02-02
CA3230652A1 (en) 2021-11-04 2023-05-11 F. Hoffmann-La Roche Ag Novel use of quinazolinone compound for the treatment of cancer
WO2024017294A1 (zh) * 2022-07-19 2024-01-25 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
CN107801378A (zh) 2015-05-22 2018-03-13 普莱希科公司 用于治疗braf‑v600相关的疾病的plx‑8394或plx‑7904
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物

Also Published As

Publication number Publication date
JP2022531609A (ja) 2022-07-07
US20220298119A1 (en) 2022-09-22
CN114787156A (zh) 2022-07-22
AU2020403443B2 (en) 2023-02-23
CR20220251A (es) 2022-07-11
JP2022124458A (ja) 2022-08-25
CA3162883A1 (en) 2021-06-17
MX2022006783A (es) 2022-07-11
AU2020403443A1 (en) 2022-05-12
PE20221778A1 (es) 2022-11-16
WO2021116055A1 (en) 2021-06-17
CL2022001529A1 (es) 2023-02-10
KR20220110554A (ko) 2022-08-08
EP4073065A1 (en) 2022-10-19
CO2022008968A2 (es) 2022-07-19
JP7108146B2 (ja) 2022-07-27
TW202136245A (zh) 2021-10-01
ZA202204675B (en) 2022-12-21
IL292161A (en) 2022-06-01
AR122351A1 (es) 2022-09-07

Similar Documents

Publication Publication Date Title
BR112022011123A2 (pt) Composto, processo para a preparação de um composto, usos de um composto, métodos para o tratamento de câncer e invenção
CY1123353T1 (el) Καινοφανης ενωση συμπυκνωμενης πυριμιδινης ή αλας εξ αυτης
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
CL2019002204A1 (es) Compuestos inhibidores del vih.
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112018071585A2 (pt) formulações de um inibidor de lsd1
BR112017019287A2 (pt) composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit
BR112016029916A2 (pt) inibidores mnk e métodos correlatos
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
EA201591339A1 (ru) Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
BR112017000550A2 (pt) compostos antiproliferativos e métodos de uso dos mesmos
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
CO2021005532A2 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
BR112018016554A2 (pt) composto de uréia, método de preparação deste e uso médico deste
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
MX2021010700A (es) Compuestos utiles en la terapia del vih.
BR112021011325A2 (pt) Derivados de rapamicina
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
BR112022000782A2 (pt) Composto, composição farmacêutica, processo para preparar um composto, composto intermediário, e, uso de um composto, ou de um sal farmaceuticamente aceitável ou solvato do mesmo, ou de uma composição farmacêutica
BR112021022255A2 (pt) Composto usado como inibidor de quinase e aplicação do mesmo

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]